Samsara BioCapital Increases Stake in Rani Therapeutics via $2 Million Direct Offering Purchase

On May 28, 2026, Samsara BioCapital, L.P. filed a Schedule 13D/A reporting an increased stake in Rani Therapeutics Holdings, Inc. (RANI). The filing indicates that on May 26, 2026, Samsara BioCapital, L.P. and Samsara Opportunity Fund, L.P. entered into a securities purchase agreement with the issuer. Through a registered direct offering that closed on May 27, 2026, the two entities purchased a combined total of approximately 1.87 million shares of Class A common stock at a price of $1.07 per share, representing a $2 million aggregate investment funded by working capital. Following this transaction, Samsara BioCapital, L.P. beneficially owns 5,661,481 shares, representing a 5.0% ownership stake. Dr. Srinivas Akkaraju, as the managing member of the general partners for both funds, is deemed to beneficially own a total of 11,322,961 shares, or approximately 9.9% of the class. The reporting persons also hold various pre-funded and common warrants, which are subject to a 9.99% beneficial ownership blocker.